The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular the present invention relates to a composition comprising an esterified anti inflammatory lipid mediator which is an ester of an anti inflammatory lipid mediator that is a reaction product of the anti inflammatory lipid mediator and a polyol wherein the majority of the anti inflammatory lipid mediator is present in an ester form. In this way the compositions are substantially free of an acid form of the anti inflammatory lipid mediators. Anti inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g. omega three and omega six fatty acids) resolvins or a metabolically stable analog protectins or a metabolically stable analog lipoxins or a metabolically stable analog prostaglandins or a metabolically stable analog retinoic acids endocannabinoids metabolites thereof and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation solution gel ointment and/or strip and/or a contact lens.
